Ishikawa and colleagues perform integrated genomic and drug-sensitivity screens with extensive PDX modeling and reveal combined XIAP and BCL2 inhibition as a vulnerability hub across AML genetic alterations.
- Mari Hashimoto
- Yoriko Saito
- Fumihiko Ishikawa